Search results
Liver Cancer Screening Benefits Patients With Cirrhosis, Study Suggests
MedPage Today· 5 days agoScreening for hepatocellular carcinoma (HCC) in liver disease patients with cirrhosis may indeed lead to a survival benefit, a retrospective analysis of data from two large ...
Dermatologists at Skin Cancer & Dermatology Institute shed light on rare skin cancers
Sierra Sun· 3 days agoThe passing of Jimmy Buffett has drawn attention to rare skin cancers, shedding light on...
...BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American...
Fort Wayne Journal Gazette· 3 days agoAntonio, Texas. The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive ...
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen...
Newswise· 6 days agoPHILADELPHIA — (Tuesday, April 30, 2024) — Hepatocellular carcinoma (HCC), or liver cancer, is an...
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
WTRF Wheeling· 7 days ago...NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been...
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 10 hours agoCastle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript May 4, 2024 Castle...
“We need to find a cure” Virginia Beach Fire joins Crush Cancer fundraiser
WAVY via Yahoo News· 5 hours agoVIRGINIA BEACH, Va. (WAVY) – Crush Cancer Hampton Roads kicked off this morning at the Cavalier Golf...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...
WTNH-TV New Haven· 2 days ago"The high complete response rate and durability of these responses observed in patients treated with...
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks via Yahoo Finance· 4 days agoCabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 3 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...